Search Results

CeloNova Announces Clinical Results From Pivotal PzF SHIELD Trial

February 2, 2017—CeloNova BioSciences, Inc. recently announced the publication of primary endpoint results from its global, multicenter PzF SHIELD clinical trial evaluating the company's Cobra Polyzene-F (PzF) nanocoated coronary stent.

Early Data Presented From First-in-Man Study of CeloNova's Cobra PzF Stent

September 16, 2014—CeloNova BioSciences, Inc. announced that results from its first-in-man clinical trial showed that the company’s Cobra PzF coronary stent system, which features a cobalt chromium super alloy and a nanothin coating of the company’s Polyzene-F polymer, is a safe and effective routine interventional treatment for real-world and complex patients with heart disease.

FDA Approves CeloNova's Cobra PzF Stent System

March 1, 2017—CeloNova BioSciences, Inc. announced US Food and Drug Administration approval of its Cobra PzF polyzene-F nanothin polymer-coated coronary stent system.

First Results Presented From Pivotal US Study of the Tryton Side Branch Stent

October 30, 2013—Tryton Medical, Inc. (Durham, NC) announced that the first results from the TRYTON pivotal investigational device exemption (IDE) coronary bifurcation trial of the Tryton side branch stent, a dedicated bifurcation device, were presented during a late-breaking clinical trial session at the TCT 2013: Transcatheter Cardiovascular Therapeutics conference in San Francisco, California.